hGH fragment comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-03-11. Where a claim depends on a specific study, the study is described rather than over-claimed.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from a fragment of human growth hormone |
| Sequence basis | hGH residues 176-191 | Commonly described as a 16-amino-acid fragment |
| Appearance | White to off-white powder | Typical for lyophilized research peptides |
| Solubility | Soluble in water or aqueous buffer | Exact solubility depends on pH and purity |
| Common synonyms | AOD9604; hGH 176-191 | Spelling and punctuation vary across sources |
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
== Career == Butler began as an instructor of medicine at Yale University (1994–1995) and later served as assistant professor at Vanderbilt University (1999–2006), where he was medical director of both the Heart Transplant and heart-lung transplant programs. In 2007, he joined Emory University as a full professor of medicine and director of the Heart Failure Research Program. At Stony Brook University, Butler served as Director of Cardiovascular Medicine and co-director of the Heart Institute (2014–2017), where he held the Charles A. Gargano Chair in Cardiology. From 2018 to 2022, he chaired the Department of Medicine at the University of Mississippi Medical Center, where he was also a professor of Physiology and Biophysics and held the Patrick H. Lehan Chair in Cardiovascular Research. Butler has combined clinical work with research, education, and leadership, directing heart failure and transplant programs at Vanderbilt and Tennessee Valley Healthcare systems. He served as Deputy Chief Science Officer for the American Heart Association (AHA) from 2009 to 2016. He has chaired committees for the Heart Failure Society of America and the American College of Cardiology, and represented the U.S. on the European Society of Cardiology Heart Failure Guidelines panel. Butler is a Fellow of the AHA, ACC, HFSA, and ESC. Butler chairs the U.S. Food and Drug Administration's Cardio-Renal Advisory Committee, co-chairs the NIH-funded HeartShare study on heart failure progression, and serves as principal investigator for several international cardiovascular trials.
== Plate production == TLC plates are usually commercially available, with standard particle size ranges to improve reproducibility. They are prepared by mixing the adsorbent, such as silica gel, with a small amount of inert binder like calcium sulfate (gypsum) and water. This mixture is spread as a thick slurry on an unreactive carrier sheet, usually glass, thick aluminum foil, or plastic. The resultant plate is dried and activated by heating in an oven for thirty minutes at 110 °C. The thickness of the absorbent layer is typically around 0.1–0.25 mm for analytical purposes and around 0.5–2.0 mm for preparative TLC. Other adsorbent coatings include aluminium oxide (alumina), or cellulose.
The Wolf Prize in Chemistry is awarded annually by the Wolf Foundation in Israel. It is one of the six Wolf Prizes established by the Foundation and has been awarded since 1978; the others are in Agriculture, Mathematics, Medicine, Physics, and Arts. The Wolf Prize in Chemistry is considered to be one of the most prestigious international chemistry awards, behind only the Nobel Prize in Chemistry. Becoming a Wolf Prize laureate has been viewed as a potential precursor to receiving the Nobel Prize. As of 2025, 13 awardees have subsequently become Nobel laureates; the most recent of those is Omar M. Yaghi.
Sources: en.wikipedia.org
=== External electrodes === The advancement of technologies like 3D printing has enabled the creation of electrodes using simple and easily accessible equipment, leading to numerous instances where these electrodes are patterned as standalone units and subsequently integrated with paper-based microfluidic devices. To this end, there have been several examples of a thermoplastic electrode patterning and their use for electrochemical sensing, for example in flow injection analysis.
Sir Henry Muck (Kit Harington), born Henry de Chartley Norton, is a wealthy aristocrat and entrepreneur, introduced as the CEO of Lumi, a green energy startup. He has a history of clinical depression following his father's suicide, and is an erratic, mercurial business leader. In series 3, Lumi prepares for a high-profile IPO underwritten by Pierpoint, with Robert having worked closely with Henry in the months leading up to the listing. On the day of the IPO, Henry behaves recklessly: he returns a major investor’s shares after being confronted over inflated earnings, takes psychedelics, and speaks to the press against advice, culminating in a physical confrontation with Robert. The listing is salvaged only after Yasmin orchestrates publicity around a meeting between Henry, his godfather Otto Mostyn, and a power-company investor, producing a last-minute boost to Lumi’s stock. In gratitude—and amid his sexual interest in Yasmin—Henry has his uncle Lord Norton suppress negative press related to her father’s disappearance. As Lumi collapses and becomes subject to a government inquest, Henry admits to Yasmin that the company largely existed to stave off his depression. Their relationship ends after sexual harassment complaints against Henry surface and he dismisses Yasmin’s concerns. After Yasmin is fired from Pierpoint and faces continued scrutiny over her father's legal scandals and death, Henry’s family reaches out to propose marriage as a means of protection and stability; she ultimately accepts, and her public image is rehabilitated through their union.
In the 19th century, artificial feeding begin to replace wet nursing, and by 1900, wet nursing no longer existed as an organized profession. Changes to the feeding of infants were both socially and technologically driven. With industrialization, more mothers worked outside the home and could less easily breastfeed their children. Technological changes including the design of artificial feeding methods and the preparation of animal milks and other milk substitutes supported a transition to artificial feeding, but with mixed success. Understanding of both nutrition and sanitation lagged behind the introduction of artificial feeding methods, contributing to extremely high infant mortality rates in the Victorian era.
== Causes == Myxedema coma represents an extreme or decompensated form of hypothyroidism. Most cases occur in patients who have been previously diagnosed with hypothyroidism, yet in some cases, hypothyroidism may not have been previously identified. Common precipitating factors of myxedema coma include:
Sources: en.wikipedia.org
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.
It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.
It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.